|
|
||
| 中文名称: |
(1S)-1,5-脱水-1-C-[4-氯-3-[(4-乙氧基苯基)甲基]苯基]-D-葡萄糖醇 |
|
| 中文别名: | ||
| 英文名称: | Dapagliflozin | |
| 英文别名: | (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol | |
| EINECS: | ||
| CAS NO.: | 461432-26-8 | |
| 分 子 式: | C21H25CLO6 | |
| 分 子 量: | 408.87 | |
物理化学性质
密度
1.349
产品用途
Dapagliflozin (rINN/USAN)is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1[1] and 2 diabetes. Although dapagliflozin's method of action would operate on either type of diabetes or other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with Type 1 diabetes.
危险品标志
安全术语
风险术语